December 3, 2009 (FinancialWire) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) (NASDAQ: CYCCP) will host a conference call on Monday, December 7 featuring Hagop M. Kantarjian, M.D., chairman and Professor, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

Dr. Kantarjian will review Phase 2 sapacitabine data in elderly patients with acute myeloid leukemia and older patients with myelodysplastic syndromes to be reported at the meeting of the American Society of Hematology on Saturday, December 5.

For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days.

New Phase 2 clinical trial results of sapacitabine for the treatment of AML and MDS will be presented at two poster presentations during the 51st annual meeting of the American Society of Hematology in New Orleans, LA, on Saturday, December 5, 2009. Presentation details are as follows:

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports, filings and conference call webcasts for companies mentioned in the news are available via Investrend Syndications (http://investrend.ar.wilink.com/?level=279). The most recently issued reports and/or recorded webcasts include Cascade Corp. (NYSE: CASC), Anadarko Petroleum Corp. (NYSE: APC), Baytex Energy Trust (NYSE: BTE) (TSX: BTE), H & Q Healthcare Investors (NYSE: HQH), H & Q Life Science Investors (NYSE: HQL), PIMCO (NYSE: PYN) (NYSE: PMX) (NYSE: PZC), PIMCO Global StocksPLUS & Income Fund (NYSE: PGP), Taiwan Greater China Fund (NYSE: TFC) and Wolseley PLC (OTC: WOSCF) (London Stock Exchange: WOS).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.